← FDA DRUG APPROVALS

FDA ANDA · ANDA207389

BUPROPION HYDROCHLORIDE

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA207389
TYPE
ANDA
ORIGINAL APPROVAL
2017-09-18
LATEST ACTION
2025-11-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

BUPROPION HYDROCHLORIDEDiscontinued
BUPROPION HYDROCHLORIDE 75MG · TABLET · ORAL
BUPROPION HYDROCHLORIDEDiscontinued
BUPROPION HYDROCHLORIDE 100MG · TABLET · ORAL

Approval history

2025-11-06Labeling · Supplement 9 · standardAP
2024-05-07Labeling · Supplement 8 · standardAP
2023-02-08Labeling · Supplement 6 · standardAP
2023-02-08Labeling · Supplement 7 · standardAP
2020-10-29Labeling · Supplement 5 · standardAP
2017-09-18UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →